OCIL Antibody (166C1309): sc-52905

OCIL Antibody (166C1309) is a mouse monoclonal IgG1 antibody that detects osteoclast inhibitory lectin (OCIL) in mouse samples through western blotting (WB). OCIL is a type II membrane-bound C-type lectin that plays a crucial role in regulating bone metabolism by inhibiting the differentiation and function of osteoclasts, which are responsible for bone resorption. This regulation is vital for maintaining bone density and overall skeletal health, as excessive osteoclast activity can lead to conditions such as osteoporosis. OCIL achieves this by binding to the natural killer cell-associated receptor NKR-P1D, thereby modulating immune responses and preventing the cytotoxic effects of natural killer cells on osteoblasts. Additionally, OCIL is expressed in various cell types, including osteoblasts and chondrocytes, and OCIL expression can be influenced by factors such as parathyroid hormone and calcitriol, highlighting OCIL′s importance in bone homeostasis and potential implications for therapies targeting bone-related diseases. Anti-OCIL antibody (166C1309) is an essential tool for researchers studying the intricate balance of bone formation and resorption, providing insights into the molecular mechanisms underlying bone health and disease.